Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center.
Necchi A, Giannatempo P, Lo Vullo S, Farè E, Raggi D, Marongiu M, Scanagatta P, Duranti L, Giovannetti R, Girelli L, Nicolai N, Piva L, Biasoni D, Torelli T, Catanzaro M, Stagni S, Maffezzini M, Gianni AM, Mariani L, Pastorino U, Salvioni R. Necchi A, et al. Among authors: mariani l. Clin Genitourin Cancer. 2015 Feb;13(1):87-93.e1. doi: 10.1016/j.clgc.2014.06.014. Epub 2014 Jun 24. Clin Genitourin Cancer. 2015. PMID: 25044148
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Morabito A, Gattuso D, Stani SC, Fanelli M, Ferraù F, De Sio L, Castellana MA, Lorusso V, Priolo D, Vitale S, Sarmiento R, Lo Vullo S, Mariani L, Gasparini G. Morabito A, et al. Among authors: mariani l. Breast Cancer Res Treat. 2004 Aug;86(3):249-57. doi: 10.1023/B:BREA.0000036898.45123.e9. Breast Cancer Res Treat. 2004. PMID: 15567941 Clinical Trial.
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M. Gasparini G, et al. Among authors: mariani l. Cancer J. 2005 May-Jun;11(3):209-16. doi: 10.1097/00130404-200505000-00007. Cancer J. 2005. PMID: 16053664 Clinical Trial.
1,182 results